Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
Combination shows consistent benefit across prespecified post-progression outcomes
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Subscribe To Our Newsletter & Stay Updated
